Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tenax Therapeutics
(NQ:
TENX
)
4.220
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tenax Therapeutics
Tenax Therapeutics Inc. (NASDAQ: TENX) Near the Top of Equities by Percentage Gain on 2/6
February 06, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Tenax Therapeutics Inc. (NASDAQ: TENX) Announces $15.6M Public Offering
February 10, 2023
Via
Investor Brand Network
Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
February 02, 2023
Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and
Via
Spotlight Growth
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
May 25, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
May 23, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
May 18, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
March 31, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions
March 30, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
NASDAQ:TENX Shareholder Alert: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc.
February 17, 2022
San Diego, CA -- (SBWIRE) -- 02/17/2022 -- Certain directors of Tenax Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties .
Via
SBWire
Investigation for Investors in Tenax Therapeutics, Inc. (NASDAQ:TENX) Shares Announced
December 13, 2021
San Diego, CA -- (SBWIRE) -- 12/13/2021 -- An investigation was announced for investors of Tenax Therapeutics, Inc. (NASDAQ:TENX) shares over potential securities laws violations by Tenax Therapeutics,...
Via
SBWire
NASDAQ:TENX Investor Notice: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc.
December 01, 2021
San Diego, CA -- (SBWIRE) -- 12/01/2021 -- Certain directors of Tenax Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update
November 16, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
NASDAQ:TENX Investor Notice: Investigation over Possible Securities Laws Violations by Tenax Therapeutics, Inc.
November 09, 2021
San Diego, CA -- (SBWIRE) -- 11/09/2021 -- Tenax Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)
October 06, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference
September 28, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update
August 17, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
August 12, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
August 05, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
July 07, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Set to Join Russell Microcap® Index
June 10, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update
May 17, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”
April 09, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders
April 07, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.